
News|Articles|June 23, 2026
Help Shape the Future of Responsible AI
Author(s)ACTO
Listen
0:00 / 0:00
Responsible AI in Life Sciences needs more than interest. It needs industry input.
Advertisement
Responsible AI is moving from concept to commercial reality in Life Sciences. This short survey invites pharma, biotech, and med device leaders to share how their teams are approaching AI governance, accountability, risk, and value. Your input will help inform the Responsible AI in Life Sciences (RAIL) initiative’s standards framework, industry report, and future guidance for responsible AI adoption.
Advertisement
Related Content
Advertisement
Advertisement
Trending on PharmExec
1
The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026
2
How 3D Printing Speeds Up Drug Production
3
Eli Lilly and Abbisko Announce Drug Development Collaboration
4
FDA Pilot Targets Faster Early-Stage Drug Trial Starts
5




